Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

12-month clinical efficacy data is released for Endeavor stent

Medtronic : 31 March, 2008  (New Product)
Data showing the clinical efficacy for Medtronic’s Endeavor drug-eluting stent has been released at the American College of Cardiology meeting.
Entitled ‘One-Year Clinical and Angiographic Results in Diabetics from Endeavor IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System Versus Taxus in de novo Native Coronary Lesions’ (2803-8) – the presentation featured an analysis of 477 diabetic patients from the Endeavor IV clinical study.

Endeavor IV is an ongoing head-to-head comparison of the Endeavor and Taxus stents in 1,548 patients. Below is a summary of the principal findings for the diabetic subset:

Endeavor IV results at 12-month follow-up for diabetic patients

Endeavor (n = 241)
Overall mortality 0.0 percent
Cardiac death 0.0 percent
Myocardial infarction 0.9 percent
Stent thrombosis 0.9 percent
Target lesion revascularization (TLR) 6.9 percent
Target vessel revascularization (TVR) 8.6 percent
Target vessel failure (TVF) 8.6 percent

Taxus (n = 236)
Overall mortality 0.9 percent
Cardiac death 0.0 percent
Myocardial infarction 0.9 percent
Stent thrombosis 0.4 percent
Target lesion revascularization (TLR) 6.8 percent
Target vessel revascularization (TVR) 9.4 percent
Target vessel failure (TVF) 10.8 percent

The safety and effectiveness of the Endeavor Stent have not been established in diabetic patients. Data would first require both FDA review and approval.
“Performance of drug-eluting stents in diabetic patients is scrutinized by doctors because diabetes complicates so many aspects of the angioplasty procedure. Achieving good efficacy is more difficult, and safety concerns are significantly increased.” said Dr Jeffrey Popma, director of Invasive Cardiovascular Services, Caritas Cardiovascular Center for the Caritas Saint Elizabeth’s Medical Center in Boston, and director of the core lab that performed the angiographic analysis for the entire Endeavor clinical program, including Endeavor IV.

Launched in the United States in February and now available in more than 120 countries worldwide, the Endeavor Stent is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length less than or equal to 27mm in native coronary arteries with reference vessel diameters of more than or equal to 2.5mm to less than or equal to 3.5mm.

Also presented at the ACC scientific session were the findings of two other substudies from the Endeavor IV clinical trial. One analysis – ‘The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System vs Taxus in De Novo Native Coronary Lesions’ (2900-103) – illustrated the artificial impact of routine angiography on revascularization rates.

The first 328 enrolled Endeavor -IV patients were selected to undergo angiography immediately post-procedure and again after eight months. These results were compared to the subsequent 1,200 patients in whom angiography was not performed. In patients receiving angiographic follow-up, the TLR rate at 12 months was 8.5 percent for Endeavor and 3.0 percent for Taxus but with no angiographic follow-up, the TLR rates were 3.6 percent for Endeavor and 3.3 percent for Taxus. These findings support the ARC recommendations that PCI clinical studies assess lesion characteristics with angiography only after the follow up required to assess the primary clinical endpoint.

A second sub-analysis – ‘The Fate of Side-Branches Among Patients Treated With Zotarolimus-Eluting and Paclitaxel-Eluting Stents: An ENDEAVOR-IV Substudy’ (2901-19) – looked at side-branch occlusion post-stenting. The analysis was conducted as doctors seek to explain the significantly increased rate of periprocedural MI with Taxus when compared to Endeavor observed in the Endeavor IV clinical trial.

The Endeavor side-branch occlusion results showed side-branch occlusion post-stenting was 2.2 percent for Endeavor and 4.8 percent for Taxus - p value (log rank) was p=0.032.

The Endeavor IV clinical trial was not prospectively designed to evaluate side-branch occlusions, so further study is warranted.

Endeavor IV is evaluating 1,548 patients at 80 clinical centres in the USA, with a primary endpoint of Target Vessel Failure (TVF) at nine months and a secondary endpoint of Major Adverse Cardiac Events (MACE) at 30-days. The principal investigator is Dr Martin B Leon of Columbia University Medical Center and the Cardiovascular Research Foundation in New York.

Endeavor IV is evaluating 1,548 patients at 80 clinical centers in the United States, with a primary endpoint of Target Vessel Failure (TVF) at nine months and a secondary endpoint of Major Adverse Cardiac Events (MACE) at 30-days. The principal investigator is Dr Martin B Leon of Columbia University Medical Center and the Cardiovascular Research Foundation in New York.

The Endeavor drug-eluting Stent is made of a cobalt alloy and is built on the same platform as Medtronic’s popular Driver bare metal stent, which features a modular architecture designed to enhance deliverability. In addition to the cytostatic drug zotarolimus,

Endeavor is coated with phosphorylcholine (PC) technology, a polymer designed to simulate the outside surface of a red blood cell and mimic the structure of the natural cell membrane. The combination of these components is designed to contribute to rapid, complete and functional
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo